The national DBSA organization is forming a peer council on Major Depressive Disorder with COMPASS Pathways, a mental health care company dedicated to accelerating access to evidence-based innovation in mental health. If you have experience with treatment-resistant depression and are interested in joining the peer council to provide feedback to COMPASS Pathways, please read DBSA’s announcement below and click the link in the “WHAT SHOULD I DO IF I AM INTERESTED?” section to take the pre-screener survey.
Putting wellness within every individual’s reach is at the core of DBSA’s mission, strategies, and programs.
DBSA is convening a peer council on behalf of one of our industry partners. Peer councils are groups of individuals with a lived experience with a mood disorder who share first-person insights and provide feedback to interested organizations such as medical product developers to help them understand what matters most to peers including delivery and development of improved mental health treatment options. Topics for peer discussion may include:
- Clinical research and development planning;
- Insights on the use of digital technology; and
- Alternative treatment awareness and marketing.
WHAT WILL I BE ASKED TO DO? Members of the peer council will be invited to participate in up to 8 online video conferences that may last up to 90-minutes each. The video conference will be recorded and transcribed. At the end of each session you participate in, you will receive a gift card as thanks for your participation.
WHO IS CONDUCTING THESE INTERVIEWS? Andrew Smith, DBSA Community Engagement Program Manager will moderate the discussions on behalf of COMPASS Pathways. COMPASS Pathways is a mental health care company dedicated to accelerating access to evidence-based innovation in mental health. COMPASS is currently researching how psilocybin therapy could help people with treatment-resistant depression. Psilocybin therapy combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support.
Early studies conducted in pioneering academic institutions have shown signals that psilocybin could be safe and helpful to patients with depression, anxiety, and other mental health conditions, when administered with psychological support from specially trained therapists. For more information on COMPASS visit: www.compasspathways.com.
WHAT ARE THE PARTICIPATION REQUIREMENTS? 18 years or older Has access and ability to participate in an online video conference, such as Zoom, Facetime, or Google Hangouts. Experience of treatment-resistant depression i.e. did not fully find wellness despite trying a variety of approved medications for depression.
WHAT SHOULD I DO IF I AM INTERESTED? If you’re interested in participating, please click here to take the pre-screener survey. We will reach out if this opportunity seems to be a good match for you.
Sharing your experiences will help put wellness within reach for many people living with mood disorders by spreading understanding of the impact and management of these life-threatening conditions.
DBSA looks forward to continued engagement with stakeholders and encourages comments to refine understanding of the clinical effectiveness and value of treatment.